EGFR-targeted therapies
Oncology· 8 reviewed drugs· 5654 cited findings behind them
What the regulatory reviews cover
This library includes several EGFR-targeted therapies that have undergone regulatory review for various indications. Rybrevant is indicated for adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations, after failure of platinum-based therapy, and in combination with lazertinib for first-line treatment. Lazcluze is indicated for the first-line treatment of adult patients with advanced NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, demonstrating a PFS HR (amivantamab + lazertinib vs osimertinib) of 0.70. Tagrisso is indicated for metastatic NSCLC, with an Objective response rate of 57.2%. Erbitux is indicated for the first-line treatment of metastatic colorectal cancer, showing a Median PFS (cetuximab with FOLFIRI) of 8.9 months.
Other drugs in this class include Erlotinib, indicated for locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen, with an Overall Survival p-value (ITT) of 0.0018. Giotrif is indicated for EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s), and for locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. Tarceva is indicated for the first-line treatment of locally advanced or metastatic NSCLC with activating EGFR mutations, reporting a Median PFS in erlotinib arm (investigator-assessed) of 9.7 months. Vectibix is also included. It is important to note that these drugs were studied in different trials, and therefore, the reported figures are not head-to-head comparisons.
The drugs — one cited result each
| Rybrevant Johnson & Johnson | geometric mean ratio of Cycle 2 Day 1 Ctrough (SC vs IV): 1.145 Unknown MAH — Rybrevant EMA EPAR variation assessment report, p.41 |
| Lazcluze Johnson & Johnson | PFS HR (amivantamab + lazertinib vs osimertinib): 0.70 Johnson & Johnson — Lazcluze EMA EPAR public assessment repo, p.92 |
| Tagrisso AstraZeneca PLC | Objective response rate: 57.2% AstraZeneca PLC — Tagrisso FDA Review, p.17 |
| Erbitux Merck B V | Median PFS (cetuximab with FOLFIRI): 8.9 IMCLONE — Erbitux FDA Review (NDA/BLA 125084, 2021), p.26 |
| Erlotinib Cheplapharm | Overall Survival p-value (ITT): 0.0018 Cheplapharm — Tarceva EMA EPAR variation assessment report, p.14 |
| Giotrif Boehringer Ingelheim | Afatinib IC50 on EGFR: 0.5 nM Boehringer Ingelheim — Giotrif EMA EPAR public assessment re, p.11 |
| Tarceva Cheplapharm | Median PFS in erlotinib arm (investigator-assessed): 9.7 Cheplapharm — Tarceva EMA EPAR variation assessment report, p.14 |
| Vectibix Amgen Inc. | ORR for panitumumab plus FOLFOX in first-line wild-type RAS mCRC with liver metastases (PLANET): 78 Amgen Inc. — Vectibix EMA EPAR variation assessment report (, p.18 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Oncology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.